About the Company
Changzhou Siyao (Siyao) is an integrated enterprise with R&D, production and sales. Siyao has got the rewards for National Hi-Tech Enterprise, Jiangsu Provincial Environment-Friendly Enterprise, National Harmonious Labor Relationship Enterprise, and 5-Star Enterprise of Changzhou for successive years.
Siyao has ranked within the top one hundred tax-paying enterprises of pharmaceuticals industries for successive 4 years. By int...
Changzhou Siyao (Siyao) is an integrated enterprise with R&D, production and sales. Siyao has got the rewards for National Hi-Tech Enterprise, Jiangsu Provincial Environment-Friendly Enterprise, National Harmonious Labor Relationship Enterprise, and 5-Star Enterprise of Changzhou for successive years.
Siyao has ranked within the top one hundred tax-paying enterprises of pharmaceuticals industries for successive 4 years. By integrating with three managing systems including national GMP certificate for pharmaceuticals, ISO14001, and OHSMS18001, three products manufactured by Siyao have got the FDA and CEP certificates, which are mainly launched in USA, Europe, Hong Kong, Southeast Asia and Africa markets.
By owning R & D center and quality center, Siyao always holds to the technology innovation. Siyao is responsible for and finishes 5 projects including National 863 Project, national technology problem-shooting and provincial technology-transferring, and also cooperates with Chinese Academy of Sciences, Peking University, Nanjing University, and Shanghai Institute of Pharmaceutical Industry and contribute to Industry-Academia-Research. Siyao owns 28 inventive patents and has applied for PET1 in USA. Siyao always insists that quality is lifeline, and actively implements Chinese new GMP and puts forward CGMP. During random checks for marketed products from the national, provincial and city authorities at all levels, the eligible ration is always 100% over more than 10 successive years.
Now three new products (Omeprazole® Enteric-Coated Capsules, Ambroxol® HCL Tablets, and Valsartan® Tablets) are Famous Brand Product of Jiangsu Province.
Siyao focuses on the products for 5 disease-treatment fields in digestive, cardiovascular, respiratory, narcotic and psychiatric, and also antihistaminic. The main products include Omeprazole ® Enteric-Coated Capsules (for peptic ulcer), Ambroxol ® HCL Tablets (expectorant), Valsartan ® Tablets (antihypertensive), Risperidone ® Tablets (antipsychotic), Fluoxetine ® HCL Tablets (one pill one week antipsychotic), Glipizide ® Controlled Release Tablets (antidiabetic), Somatostatin ® (growth hormone inhibitor), Fentanyl ® Patch (painkiller), Gabexate ® Mesylate for Injection (for pancreatitis). Main new dosage forms include DDS controlled-release preparation, slow-release preparation, gastric-release, enteric-coated preparation, laser-dig controlled-release tablets, and TTS transdermal patch. Our marketing covers more than 30 domestic provinces and cities, as well as more than 10 overseas countries and areas.
Siyao has its own API plant and Preparation Plant. With lean and rapid-reaction manufacturing and flexible productivity, Siyao specifically produces APIs and preparations. Siyao has the yearly production capacity of 100 tons for 10 APIs, among which 50 tons for USA, Europe, and Japan markets; 50 million lyophilization injections and water injections; 2 billion capsules, tablets and controlled and delayed release preparation; 10 million new form of transdermal patches.
Hi-tech and internationalization are Siyao’s aim. Internationalization is not only a choice, but also a trend. The top management and chief engineers of Siyao have attended many international professional activities including ISPE cGMP proseminar, 4th World Health Congress in Washington DC., USA, and Injection Regulatory proseminar by FDA/PDA. Through the cooperation with several domestic and overseas famous consulting companies, Siyao is introduced with current GMP knowledge and management concept, as well as the international regulatory. Siyao also establishes technology cooperation with occident and Japanese companies to further the promotion of developmental space.
“Quality is lifeline, innovation is competitive” is the core value of Siyao. Standing to the enterprise culture of “put essence for the quality product”, Siyao commits to the R & D, production and marketing of digestive, cardiovascular, respiratory, narcotic and antihistaminic products. By strengthening the international cooperation, continuing technology innovation, and culturing self inventive patents and intellectual property right system, Siyao upgrades the competitiveness and creates own brand. Siyao is on its way to challenge the new areas of chiral drugs, multi-peptide biochemical products, antitumor products, and the herbal medicines. In order to promote the universal health coverage, essential medicine, Siyao devotes itself to the insurance of the Chinese public health.
Related Companies
Market Place
